BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li B, Li S, Chen S, Li M, Lv T, Wang Q, Wang X, Wang Y, Ma H, Ou X, Zhao X, You H, Duan W, Jia J. Fenofibrate add-on therapy improves transplant-free survival in patients with primary biliary cholangitis refractory to ursodeoxycholic acid.. [DOI: 10.21203/rs.3.rs-2195709/v1] [Reference Citation Analysis]
2 Duan W, Chen S, Li S, Lv T, Li B, Wang X, Wang Y, Zhao X, Ma H, Ou X, You H, Jia J. Low incidence of primary biliary cholangitis in 139 anti-mitochondrial antibodies-positive patients with other liver or non-liver diseases. Hepatol Commun 2022. [PMID: 35998274 DOI: 10.1002/hep4.2067] [Reference Citation Analysis]
3 Wang C, Shi Y, Wang X, Ma H, Liu Q, Gao Y, Niu J. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis. Front Immunol 2022;13:940688. [DOI: 10.3389/fimmu.2022.940688] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Park J, Kim J, Kim S, Jung JH, Jang M, Park S, Lee M, Kim H, Suk KT, Kim DJ. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics. Biomedicines 2022;10:1288. [DOI: 10.3390/biomedicines10061288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Bauer A, Habior A. Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis. Front Immunol 2022;13:885229. [DOI: 10.3389/fimmu.2022.885229] [Reference Citation Analysis]